181 related articles for article (PubMed ID: 32707820)
1. Targeting STAT3 and STAT5 in Cancer.
de Araujo ED; Keserű GM; Gunning PT; Moriggl R
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32707820
[TBL] [Abstract][Full Text] [Related]
2. Activation of STAT3 and STAT5 Signaling in Epithelial Ovarian Cancer Progression: Mechanism and Therapeutic Opportunity.
Wu CJ; Sundararajan V; Sheu BC; Huang RY; Wei LH
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31861720
[No Abstract] [Full Text] [Related]
3. Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers.
Brachet-Botineau M; Polomski M; Neubauer HA; Juen L; Hédou D; Viaud-Massuard MC; Prié G; Gouilleux F
Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31963765
[TBL] [Abstract][Full Text] [Related]
4. Identification of coding and non-coding mutational hotspots in cancer genomes.
Piraino SW; Furney SJ
BMC Genomics; 2017 Jan; 18(1):17. PubMed ID: 28056774
[TBL] [Abstract][Full Text] [Related]
5. STAT3 and STAT5 Targeting for Simultaneous Management of Melanoma and Autoimmune Diseases.
Logotheti S; Pützer BM
Cancers (Basel); 2019 Sep; 11(10):. PubMed ID: 31569642
[TBL] [Abstract][Full Text] [Related]
6. Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer.
Wingelhofer B; Neubauer HA; Valent P; Han X; Constantinescu SN; Gunning PT; Müller M; Moriggl R
Leukemia; 2018 Aug; 32(8):1713-1726. PubMed ID: 29728695
[TBL] [Abstract][Full Text] [Related]
7. Distinct roles of STAT3 and STAT5 in the pathogenesis and targeted therapy of breast cancer.
Walker SR; Xiang M; Frank DA
Mol Cell Endocrinol; 2014 Jan; 382(1):616-621. PubMed ID: 23531638
[TBL] [Abstract][Full Text] [Related]
8. STAT5 outcompetes STAT3 to regulate the expression of the oncogenic transcriptional modulator BCL6.
Walker SR; Nelson EA; Yeh JE; Pinello L; Yuan GC; Frank DA
Mol Cell Biol; 2013 Aug; 33(15):2879-90. PubMed ID: 23716595
[TBL] [Abstract][Full Text] [Related]
9. Chronic Inhibition of STAT3/STAT5 in Treatment-Resistant Human Breast Cancer Cell Subtypes: Convergence on the ROS/SUMO Pathway and Its Effects on xCT Expression and System xc- Activity.
Linher-Melville K; Nashed MG; Ungard RG; Haftchenary S; Rosa DA; Gunning PT; Singh G
PLoS One; 2016; 11(8):e0161202. PubMed ID: 27513743
[TBL] [Abstract][Full Text] [Related]
10. Long non-coding RNA RP11-468E2.5 curtails colorectal cancer cell proliferation and stimulates apoptosis via the JAK/STAT signaling pathway by targeting STAT5 and STAT6.
Jiang L; Zhao XH; Mao YL; Wang JF; Zheng HJ; You QS
J Exp Clin Cancer Res; 2019 Nov; 38(1):465. PubMed ID: 31718693
[TBL] [Abstract][Full Text] [Related]
11. Constitutive activation of STAT3 is predictive of poor prognosis in human gastric cancer.
Xiong H; Du W; Wang JL; Wang YC; Tang JT; Hong J; Fang JY
J Mol Med (Berl); 2012 Sep; 90(9):1037-46. PubMed ID: 22328012
[TBL] [Abstract][Full Text] [Related]
12. Reciprocal effects of STAT5 and STAT3 in breast cancer.
Walker SR; Nelson EA; Zou L; Chaudhury M; Signoretti S; Richardson A; Frank DA
Mol Cancer Res; 2009 Jun; 7(6):966-76. PubMed ID: 19491198
[TBL] [Abstract][Full Text] [Related]
13. Cryptotanshinone suppresses key onco-proliferative and drug-resistant pathways of chronic myeloid leukemia by targeting STAT5 and STAT3 phosphorylation.
Dong B; Liang Z; Chen Z; Li B; Zheng L; Yang J; Zhou H; Qu L
Sci China Life Sci; 2018 Sep; 61(9):999-1009. PubMed ID: 30054832
[TBL] [Abstract][Full Text] [Related]
14. Visualization of Stat3 and Stat5 transactivation activity with specific response element dependent reporter constructs integrated into lentiviral gene transfer vectors.
Gäbel K; Bednorz NL; Klemmt P; Vafaizadeh V; Borghouts C; Groner B
Horm Mol Biol Clin Investig; 2010 Jan; 1(3):127-37. PubMed ID: 25961188
[TBL] [Abstract][Full Text] [Related]
15. The genes induced by signal transducer and activators of transcription (STAT)3 and STAT5 in mammary epithelial cells define the roles of these STATs in mammary development.
Clarkson RW; Boland MP; Kritikou EA; Lee JM; Freeman TC; Tiffen PG; Watson CJ
Mol Endocrinol; 2006 Mar; 20(3):675-85. PubMed ID: 16293640
[TBL] [Abstract][Full Text] [Related]
16. Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.
Gleixner KV; Schneeweiss M; Eisenwort G; Berger D; Herrmann H; Blatt K; Greiner G; Byrgazov K; Hoermann G; Konopleva M; Waliul I; Cumaraswamy AA; Gunning PT; Maeda H; Moriggl R; Deininger M; Lion T; Andreeff M; Valent P
Haematologica; 2017 Sep; 102(9):1519-1529. PubMed ID: 28596283
[TBL] [Abstract][Full Text] [Related]
17. STAT3 and STAT5 Signaling Thresholds Determine Distinct Regulation for Innate Receptor-Induced Inflammatory Cytokines, and
Hedl M; Sun R; Huang C; Abraham C
J Immunol; 2019 Dec; 203(12):3325-3338. PubMed ID: 31732533
[TBL] [Abstract][Full Text] [Related]
18. Direct Targeting Options for STAT3 and STAT5 in Cancer.
Orlova A; Wagner C; de Araujo ED; Bajusz D; Neubauer HA; Herling M; Gunning PT; Keserű GM; Moriggl R
Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31817042
[TBL] [Abstract][Full Text] [Related]
19. Differential activation of Stat3 and Stat5 by distinct regions of the growth hormone receptor.
Sotiropoulos A; Moutoussamy S; Renaudie F; Clauss M; Kayser C; Gouilleux F; Kelly PA; Finidori J
Mol Endocrinol; 1996 Aug; 10(8):998-1009. PubMed ID: 8843416
[TBL] [Abstract][Full Text] [Related]
20. Dual-inhibitors of STAT5 and STAT3: studies from molecular docking and molecular dynamics simulations.
Shao S; Yu R; Yu Y; Li Y
J Mol Model; 2014 Aug; 20(8):2399. PubMed ID: 25098340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
